Ebola Vaccine Passes Early Hurdle

November 28, 2014 7:00 PM

11 0

In a small phase I clinical trial in healthy volunteers, the vaccine candidate yielded immune responses similar to those that protected nonhuman primates in preclinical studies, according to Julie Ledgerwood, DO, of the National Institute of Allergy and Infectious Diseases in Bethesda, Md., and colleagues.

There were no major safety concerns in the 20-person trial, although adverse effects were more common at the higher of two doses tested -- the dose that yielded the best immune responses, Ledgerwood and colleagues reported online in the New England Journal of Medicine.

Read more

To category page